Volume 4.33 | Aug 23

Mammary Cell News 4.33 August 23, 2012
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites
Findings revealed that metastasis-initiating cells need to overcome organ-specific anti-metastatic signals in order to undergo reactivation. [Cell] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)


Effect of Inhibition of the Lysophosphatidic Acid Receptor 1 on Metastasis and Metastatic Dormancy in Breast Cancer
Researchers identified Debio-0719 as a drug candidate with metastasis suppressor activity, inducing dormancy at secondary tumor sites. [J Natl Cancer Inst] Abstract

FAM83B Mediates EGFR- and RAS-Driven Oncogenic Transformation
Ablation of family with sequence similarity 83, member B (FAM83B) inhibited the proliferation and malignant phenotype of tumor-derived cells or RAS-transformed human mammary epithelial cells, implicating FAM83B as a key intermediary in EGFR/RAS/MAPK signaling. [J Clin Invest] Full Article | Press Release

An Integrated Transcriptional Regulatory Circuit that Reinforces the Breast Cancer Stem Cell State
Using a genetic screen in an inducible model of cancer stem-like cell (CSC) formation in a breast cell line, researchers identified microRNAs that inhibit CSC growth and are down-regulated in CSCs. [Proc Natl Acad Sci USA] Abstract

MLK3 Regulates Paxillin Phosphorylation in Chemokine-Mediated Breast Cancer Cell Migration and Invasion to Drive Metastasis
Researchers provide evidence that MLK3 is required for chemokine-induced invasion of basal breast cancer cells. [Cancer Res] Abstract

Decreased eIF3e/Int6 Expression Causes Epithelial-to-Mesenchymal Transition in Breast Epithelial Cells
To gain a better understanding of the role of eIF3e/Int6 in breast cancer, investigators examined the effects of decreased eIF3e/Int6 expression in an immortalized breast epithelial cell line. [Oncogene] Abstract

Tamoxifen Regulates Cell Fate through Mitochondrial Estrogen Receptor Beta in Breast Cancer
Researchers found that tamoxifen engaged mitochondrial estrogen receptor beta as an antagonist in MCF7-BK cells, increasing reactive oxygen species concentrations from the mitochondria that were required for cytotoxicity. [Oncogene] Abstract

Oncolytic Vaccinia Virus GLV-1h68 Strain Shows Enhanced Replication in Human Breast Cancer Stem-Like Cells in Comparison to Breast Cancer Cells
Investigators aimed to demonstrate whether the oncolytic vaccinia virus kills cancer stem cells that are resistant to irradiation and chemotherapy. [J Transl Med] Abstract | Full Article

Treatment of Breast Cancer Stem Cells with Oncolytic Herpes Simplex Virus
Scientists demonstrated that oncolytic herpes simplex viruses (oHSVs) are effective against breast cancer stem cells and suggested that oHSVs could be a beneficial strategy for treating breast cancer patients. [Cancer Gene Ther] Full Article


Relationship between Mammographic Density and Breast Cancer Death in the Breast Cancer Surveillance Consortium
Scientists found that high mammographic breast density was not associated with risk of death from breast cancer or death from any cause after accounting for other patient and tumor characteristics. [J Natl Cancer Inst] Abstract | Press Release | Related Interview

Soluble KIT Correlates with Clinical Outcome in Patients with Metastatic Breast Cancer Treated with Sunitinib
The ability of soluble KIT, vascular endothelial growth factor-A (VEGF-A), soluble VEGF receptor-2 (sVEGFR-2), and sVEGFR-3 to predict clinical outcome was analyzed in 61 patients with previously treated metastatic breast cancer in a phase II study of sunitinib monotherapy. [J Transl Med] Abstract | Full Article

PPAR Signaling Pathway May Be an Important Predictor of Breast Cancer Response to Neoadjuvant Chemotherapy
To predict the responses to chemotherapy, researchers performed a phase II trial of neoadjuvant chemotherapy using a weekly paclitaxel plus carboplatin regimen for stage II/III breast cancer and assessed the correlation between baseline gene expression and the tumor response to treatment. [Cancer Chemother Pharmacol] Abstract

PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video

Based on your feedback, we’ve added a Reviews section to Mammary Cell News

Body Composition Changes in Females Treated for Breast Cancer: A Review of the Evidence
This review characterized the patterns of body composition change in females treated for breast cancer including only studies that utilize imaging technologies to quantify adipose tissue and lean body mass. [Breast Cancer Res Treat] Abstract

Lapatinib, Trastuzumab or the Combination Added to Preoperative Chemotherapy for Breast Cancer: A Meta-Analysis of Randomized Evidence
This review compared the efficacy and safety of the addition of lapatinib versus trastuzumab or their combination to neoadjuvant chemotherapy in HER2-positive breast cancer. [Breast Cancer Res Treat] Abstract


Department of Health Presents Nearly $3.5 Million in Health Research Grants
Department of Health Secretary Dr. Eli N. Avila presented nearly $3.5 million in Commonwealth Universal Research Enhancement Program grants to support four, two-year research projects focused on cancer treatment technologies. [Commonwealth of Pennsylvania] Press Release

CRI Awards $10 Million to Advance Immune-Based Cancer Treatments
Cancer Research Institute, Inc. (CRI) announced that it has committed more than $10 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development at research centers worldwide. [Cancer Research Institute] Press Release

DARA BioSciences Announces Soltamox® Distribution Partnership in the Commonwealth of Puerto Rico
DARA BioSciences, Inc. announced that it has entered into an exclusive distribution agreement with Seyer Pharmatec Inc. for the sale and distribution of Soltamox® in the Commonwealth of Puerto Rico. Soltamox is the first and only FDA-approved oral liquid formulation of tamoxifen citrate, a first-line therapy for the prevention and treatment of breast cancer. [DARA BioSciences, Inc.] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 30th Annual Miami Breast Cancer Conference
March 7-10, 2013
Miami Beach, United States

our events page to see a complete list of events in the mammary cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Position – Breast Cancer (Albert Einstein College of Medicine)

Posdoctoral Position – Androgen Dependent Breast Cancer (The Institute of Cancer Research)

Posdoctoral Position(s) – Receptor Trafficking in Mammary Carcinogenesis (The Beatson Institute for Cancer Research)

Principal Investigator(s) – Cancer Research (National University of Singapore)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us